ストックスクリーナーアプリを入手
1.04
0.00%
0.00
プレマーケット:
1.15
0.11
+10.58%
前日終値:
$1.04
開ける：
$1.03
24時間の取引高:
59,789
Relative Volume:
0.76
時価総額：
$35.19M
収益：
-
当期純損益:
$-13.27M
株価収益率:
-6.3415
EPS:
-0.164
ネットキャッシュフロー:
$-7.70M
1週間 パフォーマンス:
+0.77%
1か月 パフォーマンス:
-1.89%
6か月 パフォーマンス:
-37.35%
1年 パフォーマンス:
-35.80%
1日の値動き範囲:
$1.03
$1.15
1週間の範囲:
$1.01
$1.15
52週間の値動き範囲:
$0.8075
$1.90
Okyo Pharma Limited Stock (OKYO) Company Profile
OKYO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.04 | 35.19M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Okyo Pharma Limited (OKYO) 最新ニュース
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
OKYO Pharma Limited ("OKYO" or the "Company")Conversion of CLNs, cashless exercise of Warrants, and issue of equity - Marketscreener.com
OKYO Pharma (NASDAQ:OKYO) & Adaptimmune Therapeutics (NASDAQ:ADAP) Head-To-Head Review - Defense World
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.7% – Should You Buy? - Defense World
OKYO Pharma : Results of AGM 2024 - Marketscreener.com
Contrasting Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO) - Defense World
Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN) - Defense World
OKYO Pharma (NASDAQ:OKYO) Trading Down 1% – What’s Next? - Defense World
OKYO Pharma to join BTIG Ophthalmology Day By Investing.com - Investing.com Canada
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference - GlobeNewswire
OKYO Pharma to join BTIG Ophthalmology Day - Investing.com
OKYO Pharma to Highlight Innovations at BTIG Conference - TipRanks
OKYO Pharma CEO to present at BTIG Ophthalmology Day - Proactive Investors USA
OKYO Pharma to Present at BTIG Ophthalmology Day, Showcases Neuropathic Pain Treatment | OKYO Stock News - StockTitan
Notice of AGM: December 2024 - Marketscreener.com
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
OKYO Pharma (LON:OKYO) Trading Down 24.3% – Here’s What Happened - Defense World
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference - Proactive Investors USA
OKYO Pharma Advances in Ocular Treatment Trials - TipRanks
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference - The Manila Times
OKYO Pharma Limited to Present at International Tear Film & Ocular Surface Society Conference - Marketscreener.com
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialICYMI - Proactive Investors Australia
OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain - Proactive Investors Australia
H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares - Investing.com India
OKYO Pharma doses first subject in OK-101 Phase II trial for NCP - Clinical Trials Arena
H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares By Investing.com - Investing.com South Africa
Wainwright sustains Buy rating on OKYO Pharma shares on clinical trial progress - Investing.com
OKYO Pharma launches Phase 2 trial for NCP treatment - Investing.com India
OKYO Pharma commences Phase 2 trial for ocular pain treatment By Investing.com - Investing.com Australia
OKYO Pharma launches Phase 2 trial for NCP treatment By Investing.com - Investing.com Australia
OKYO Pharma shares surge on Phase 2 neuropathic corneal pain trial update - Proactive financial news
OKYO Pharma commences Phase 2 trial for ocular pain treatment - Investing.com India
OKYO Pharma Begins Key Trial for Eye Pain Therapy - TipRanks
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire Inc.
Q2 Earnings Estimate for OKYO Pharma Issued By HC Wainwright - Defense World
H.C. Wainwright maintains Buy rating on OKYO Pharma shares By Investing.com - Investing.com UK
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug - Yahoo Finance
OKYO Pharma begins phase 2 trial for NCP treatment - Investing.com
OKYO Pharma begins phase 2 trial for NCP treatment By Investing.com - Investing.com UK
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment - Proactive Investors USA
OKYO begins patient enrollment for Phase 2 NCP trial By Investing.com - Investing.com Australia
OKYO begins patient enrollment for Phase 2 NCP trial - Investing.com
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - GlobeNewswire
Okyo Pharma Limited (OKYO) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):